Abstract
Background and aims Chronic pain is a major part of the disease burden in Charcot-Marie-Tooth (CMT) disease. Current pharmacotherapies to manage symptoms of CMT disease, particularly pain, are inadequate. This exploratory study examined the patient reported efficacy of medical cannabis among CMT patients.
Methods Participants (N = 56; 71.4% female; Age = 48.9, SD = 14.6; 48.5% CMT1) were recruited though the Hereditary Neuropathy Foundation’s Global Registry for Inherited Neuropathies. The online survey contained 52 multiple choice questions about demographics, medical cannabis use, symptomology, efficacy, and adverse effects.
Results When asked about how much relief they experience from using cannabis as a method of symptom relief, respondents reported an average of 69.6% (SEM + 2.6). Women were more likely to report experiencing pain than men (p < .05). Participants who perceived support from their providers were more likely to inform them of their cannabis use (p < .05).
Interpretation Patients reported that cannabis was effective to manage symptoms. More prospective and controlled research needs to be conducted to better serve and optimize the potential use of cannabis to treat CMT.
Graphical Abstract Patient Reported Outcomes of Medical Cannabis for Managing Pain in Patients with Charcot-Marie-Tooth Disease
Priscilla C. Canals, Alexia G. Aguilar, Gregory T. Carter, Marion McNabb, Andrew M. Westerkamp, Miyabe Shields, Meg D’Elia, Joy Aldrich, Robert N. Moore, Allison T. Moore, Brian J. Piper*
There is no prior research of medical cannabis experiences among Charcot-Marie-Tooth (CMT) patients.
CMT patients (N=56) were recruited though the Hereditary Neuropathy Foundation’s Global Registry for Inherited Neuropathies and completed an online survey.
Symptom relief from using cannabis was moderately-high (70% + 3).
CMT patients that received support from their providers were significantly more likely to inform them of their cannabis use.
These descriptive results should be verified using prospective and randomized controlled trials.
Competing Interest Statement
BJP was part of an osteoarthritis research team supported by Pfizer and Eli Lilly (2019-2021) and is supported by the Pennsylvania Academic Clinical Research Center and Health Resources Services Administration (D34HP31025). CMS, AW, and MD are employed in the cannabis industry. The other authors report no disclosures.
Funding Statement
This study did receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Advarra gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
